Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
National University Hospital
Trial Status: Ongoing, Recruiting
Not Yet Recruiting
Principal Investigator(s):
Dr David Tai Wai Meng
Dr Robert John Walsh
Published by HT Digital Content Services with permission from Health Daily Digest....